scispace - formally typeset
M

Mao Zhang

Researcher at Peking University

Publications -  13
Citations -  1053

Mao Zhang is an academic researcher from Peking University. The author has contributed to research in topics: Heart failure & Medicine. The author has an hindex of 7, co-authored 10 publications receiving 737 citations. Previous affiliations of Mao Zhang include Cardiovascular Institute of the South.

Papers
More filters
Journal ArticleDOI

CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress-induced myocardial necroptosis

TL;DR: It is shown that receptor-interacting protein 3 (RIP3) triggers myocardial necroptosis, in addition to apoptosis and inflammation, through activation of Ca2+-calmodulin–dependent protein kinase (CaMKII) rather than through the well-established RIP3 partners RIP1 and MLKL.
Journal ArticleDOI

Central role of E3 ubiquitin ligase MG53 in insulin resistance and metabolic disorders

TL;DR: In this article, muscle-specific mitsugumin 53 (MG53; also called TRIM72) mediates the degradation of the insulin receptor and insulin receptor substrate 1 (IRS1), and when upregulated, causes metabolic syndrome featuring insulin resistance, obesity, hypertension and dyslipidaemia.
Journal ArticleDOI

Hominoid-Specific De Novo Protein-Coding Genes Originating from Long Non-Coding RNAs

TL;DR: It is suggested that at least a portion of long non-coding RNAs, especially those with active and regulated transcription, may serve as a birth pool for protein-c coding genes, which are then further optimized at the transcriptional level.
Journal ArticleDOI

Programmed necrosis in cardiomyocytes: mitochondria, death receptors and beyond.

TL;DR: The regulatory mechanisms of the programmed necrosis of cardiomyocytes, that is, the intrinsic (mitochondrial) and extrinsic (death receptor) pathways are summarized and the role of this programmed Necrosis in various heart diseases is also delineated.
Journal ArticleDOI

CaMKII-δ9 promotes cardiomyopathy through disrupting UBE2T-dependent DNA repair.

TL;DR: The role of CaMKII-δ9, a previously less-studied isoform, in driving cardiomyopathy is reported and is marked as an important therapeutic target for cardiomeopathy and heart failure.